Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study
Ischemia-modified albumin (IMA) is a sensitive biomarker of myocardial ischemia. However, data on IMA levels in acute heart failure (HF) are still lacking. In this study, we aimed to evaluate serum IMA levels in acute decompensated HF and the effects of dobutamine and levosimendan treatments on IMA...
Gespeichert in:
| Veröffentlicht in: | Anatolian journal of cardiology 2015-08, Vol.15 (8), p.611-617 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 617 |
|---|---|
| container_issue | 8 |
| container_start_page | 611 |
| container_title | Anatolian journal of cardiology |
| container_volume | 15 |
| creator | Çavuşoğlu, Yüksel Korkmaz, Şule Demirtaş, Selda Gencer, Erkan Şaşmaz, Hatice Mutlu, Fezan Güneş, Hakan Mert, Uğur Kadir Özdemir, Sedat Kalaycı, Süleyman Yılmaz, Mehmet Birhan |
| description | Ischemia-modified albumin (IMA) is a sensitive biomarker of myocardial ischemia. However, data on IMA levels in acute heart failure (HF) are still lacking. In this study, we aimed to evaluate serum IMA levels in acute decompensated HF and the effects of dobutamine and levosimendan treatments on IMA levels.
This was a prospective, multicenter study that included 70 patients hospitalized with acute decompensated HF and left ventricular ejection fraction < 35%. Blood samples for IMA measurements were obtained on admission and 24-48 h after the initiation of HF therapy. Twenty-nine patients were treated with standard HF therapy, 18 received levosimendan, and 23 received dobutamine in addition to standard of care. A single serum specimen was also collected from 32 healthy individuals each. IMA concentrations were measured by the albumin cobalt binding colorimetric assay, and the results were given in absorbance units (AU). Independent and paired sample t-tests, Mann-Whitney U test, and Wilcoxon signed-rank test were used for the analysis.
In patients with acute decompensated HF, the serum concentration of IMA was significantly higher than those of healthy subjects (0.894 ± 0.23 AU vs. 0.379 ± 0.08 AU, p < 0.001). Overall, the IMA levels significantly decreased after 24-48 h of HF therapy (0.894 ± 0.23 AU and 0.832 ± 0.18 AU, p = 0.013). Furthermore, the IMA levels were also found to significantly decrease with standard HF therapy (1.041 ± 0.28 vs. 0.884 ± 0.15 AU, p = 0.041), with levosimendan (0.771 ± 0.18 vs. 0.728 ± 0.18 AU, p = 0.046) and also with dobutamine (0.892 ± 0.18 vs. 0.820 ± 0.13 AU, p = 0.035).
Patients with acute decompensated HF had elevated IMA levels, and appropriate HF therapy significantly reduced the serum IMA levels. Dobutamine or levosimendan did not increase the IMA levels, suggesting a lower potential in inducing myocardial ischemia when used in recommended doses. |
| doi_str_mv | 10.5152/akd.2015.6156 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5336859</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3802379091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-9ecbf667afae8faa95c86c16e6575189cd2e190b8a309a4bdde4e449a42142b83</originalsourceid><addsrcrecordid>eNpdkUtv1TAQhS0EolXpki2yxIZNLnYcOwkLpKqi7ZWK2MDamtgTrksSX_wo6k_gX-P0cQUsLI_Gn8_4-BDymrON5LJ-Dz_spmZcbhSX6hk5rnnTV3Xd8ueHWokjchrjDWOMt6LjXL0kR6XLuGiaY_J7G80OZwfV7K0bHVoK05Bnt9AJb3GKtFR7SA6XFOkvl3YUTE5ILRo_73GJkMqdHUJIdAQ35YA0Bbzv3uPWDzlBEUTqwyrqo5txsbB8oNvPZ9XVBY0p27tX5MUIU8TTx_2EfLv49PX8qrr-crk9P7uuTNPJVPVohlGpFkbAbgTopemU4QqVbCXvemNr5D0bOhCsh2awFhtsmlKWD6mHTpyQjw-6-zzMaE0xFmDS--BmCHfag9P_nixup7_7Wy2FUJ3si8C7R4Hgf2aMSc8uGpwmWNDnqHnLWimFlOust_-hNz6HpdgrFGdqXXWhqgfKBB9jwPHwGM70mrMuOes1Z73mXPg3fzs40E-pij-sR6am</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710671062</pqid></control><display><type>article</type><title>Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Çavuşoğlu, Yüksel ; Korkmaz, Şule ; Demirtaş, Selda ; Gencer, Erkan ; Şaşmaz, Hatice ; Mutlu, Fezan ; Güneş, Hakan ; Mert, Uğur Kadir ; Özdemir, Sedat ; Kalaycı, Süleyman ; Yılmaz, Mehmet Birhan</creator><creatorcontrib>Çavuşoğlu, Yüksel ; Korkmaz, Şule ; Demirtaş, Selda ; Gencer, Erkan ; Şaşmaz, Hatice ; Mutlu, Fezan ; Güneş, Hakan ; Mert, Uğur Kadir ; Özdemir, Sedat ; Kalaycı, Süleyman ; Yılmaz, Mehmet Birhan</creatorcontrib><description>Ischemia-modified albumin (IMA) is a sensitive biomarker of myocardial ischemia. However, data on IMA levels in acute heart failure (HF) are still lacking. In this study, we aimed to evaluate serum IMA levels in acute decompensated HF and the effects of dobutamine and levosimendan treatments on IMA levels.
This was a prospective, multicenter study that included 70 patients hospitalized with acute decompensated HF and left ventricular ejection fraction < 35%. Blood samples for IMA measurements were obtained on admission and 24-48 h after the initiation of HF therapy. Twenty-nine patients were treated with standard HF therapy, 18 received levosimendan, and 23 received dobutamine in addition to standard of care. A single serum specimen was also collected from 32 healthy individuals each. IMA concentrations were measured by the albumin cobalt binding colorimetric assay, and the results were given in absorbance units (AU). Independent and paired sample t-tests, Mann-Whitney U test, and Wilcoxon signed-rank test were used for the analysis.
In patients with acute decompensated HF, the serum concentration of IMA was significantly higher than those of healthy subjects (0.894 ± 0.23 AU vs. 0.379 ± 0.08 AU, p < 0.001). Overall, the IMA levels significantly decreased after 24-48 h of HF therapy (0.894 ± 0.23 AU and 0.832 ± 0.18 AU, p = 0.013). Furthermore, the IMA levels were also found to significantly decrease with standard HF therapy (1.041 ± 0.28 vs. 0.884 ± 0.15 AU, p = 0.041), with levosimendan (0.771 ± 0.18 vs. 0.728 ± 0.18 AU, p = 0.046) and also with dobutamine (0.892 ± 0.18 vs. 0.820 ± 0.13 AU, p = 0.035).
Patients with acute decompensated HF had elevated IMA levels, and appropriate HF therapy significantly reduced the serum IMA levels. Dobutamine or levosimendan did not increase the IMA levels, suggesting a lower potential in inducing myocardial ischemia when used in recommended doses.</description><identifier>ISSN: 2149-2263</identifier><identifier>EISSN: 2149-2271</identifier><identifier>DOI: 10.5152/akd.2015.6156</identifier><identifier>PMID: 26301344</identifier><language>eng</language><publisher>Turkey: Kare Publishing</publisher><subject>Adolescent ; Adult ; Aged ; Biomarkers - blood ; Cardiotonic Agents - administration & dosage ; Dobutamine - administration & dosage ; Female ; Heart Failure - blood ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Humans ; Hydrazones - administration & dosage ; Infusions, Intravenous ; Male ; Middle Aged ; Original Investigation ; Prospective Studies ; Pyridazines - administration & dosage ; Serum Albumin ; Serum Albumin, Human ; Treatment Outcome ; Turkey ; Young Adult</subject><ispartof>Anatolian journal of cardiology, 2015-08, Vol.15 (8), p.611-617</ispartof><rights>Copyright Aves Yayincilik Ltd. STI. Aug 2015</rights><rights>Copyright © 2015 Turkish Society of Cardiology 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-9ecbf667afae8faa95c86c16e6575189cd2e190b8a309a4bdde4e449a42142b83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336859/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336859/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26301344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Çavuşoğlu, Yüksel</creatorcontrib><creatorcontrib>Korkmaz, Şule</creatorcontrib><creatorcontrib>Demirtaş, Selda</creatorcontrib><creatorcontrib>Gencer, Erkan</creatorcontrib><creatorcontrib>Şaşmaz, Hatice</creatorcontrib><creatorcontrib>Mutlu, Fezan</creatorcontrib><creatorcontrib>Güneş, Hakan</creatorcontrib><creatorcontrib>Mert, Uğur Kadir</creatorcontrib><creatorcontrib>Özdemir, Sedat</creatorcontrib><creatorcontrib>Kalaycı, Süleyman</creatorcontrib><creatorcontrib>Yılmaz, Mehmet Birhan</creatorcontrib><title>Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study</title><title>Anatolian journal of cardiology</title><addtitle>Anatol J Cardiol</addtitle><description>Ischemia-modified albumin (IMA) is a sensitive biomarker of myocardial ischemia. However, data on IMA levels in acute heart failure (HF) are still lacking. In this study, we aimed to evaluate serum IMA levels in acute decompensated HF and the effects of dobutamine and levosimendan treatments on IMA levels.
This was a prospective, multicenter study that included 70 patients hospitalized with acute decompensated HF and left ventricular ejection fraction < 35%. Blood samples for IMA measurements were obtained on admission and 24-48 h after the initiation of HF therapy. Twenty-nine patients were treated with standard HF therapy, 18 received levosimendan, and 23 received dobutamine in addition to standard of care. A single serum specimen was also collected from 32 healthy individuals each. IMA concentrations were measured by the albumin cobalt binding colorimetric assay, and the results were given in absorbance units (AU). Independent and paired sample t-tests, Mann-Whitney U test, and Wilcoxon signed-rank test were used for the analysis.
In patients with acute decompensated HF, the serum concentration of IMA was significantly higher than those of healthy subjects (0.894 ± 0.23 AU vs. 0.379 ± 0.08 AU, p < 0.001). Overall, the IMA levels significantly decreased after 24-48 h of HF therapy (0.894 ± 0.23 AU and 0.832 ± 0.18 AU, p = 0.013). Furthermore, the IMA levels were also found to significantly decrease with standard HF therapy (1.041 ± 0.28 vs. 0.884 ± 0.15 AU, p = 0.041), with levosimendan (0.771 ± 0.18 vs. 0.728 ± 0.18 AU, p = 0.046) and also with dobutamine (0.892 ± 0.18 vs. 0.820 ± 0.13 AU, p = 0.035).
Patients with acute decompensated HF had elevated IMA levels, and appropriate HF therapy significantly reduced the serum IMA levels. Dobutamine or levosimendan did not increase the IMA levels, suggesting a lower potential in inducing myocardial ischemia when used in recommended doses.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Cardiotonic Agents - administration & dosage</subject><subject>Dobutamine - administration & dosage</subject><subject>Female</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Hydrazones - administration & dosage</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Investigation</subject><subject>Prospective Studies</subject><subject>Pyridazines - administration & dosage</subject><subject>Serum Albumin</subject><subject>Serum Albumin, Human</subject><subject>Treatment Outcome</subject><subject>Turkey</subject><subject>Young Adult</subject><issn>2149-2263</issn><issn>2149-2271</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtv1TAQhS0EolXpki2yxIZNLnYcOwkLpKqi7ZWK2MDamtgTrksSX_wo6k_gX-P0cQUsLI_Gn8_4-BDymrON5LJ-Dz_spmZcbhSX6hk5rnnTV3Xd8ueHWokjchrjDWOMt6LjXL0kR6XLuGiaY_J7G80OZwfV7K0bHVoK05Bnt9AJb3GKtFR7SA6XFOkvl3YUTE5ILRo_73GJkMqdHUJIdAQ35YA0Bbzv3uPWDzlBEUTqwyrqo5txsbB8oNvPZ9XVBY0p27tX5MUIU8TTx_2EfLv49PX8qrr-crk9P7uuTNPJVPVohlGpFkbAbgTopemU4QqVbCXvemNr5D0bOhCsh2awFhtsmlKWD6mHTpyQjw-6-zzMaE0xFmDS--BmCHfag9P_nixup7_7Wy2FUJ3si8C7R4Hgf2aMSc8uGpwmWNDnqHnLWimFlOust_-hNz6HpdgrFGdqXXWhqgfKBB9jwPHwGM70mrMuOes1Z73mXPg3fzs40E-pij-sR6am</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Çavuşoğlu, Yüksel</creator><creator>Korkmaz, Şule</creator><creator>Demirtaş, Selda</creator><creator>Gencer, Erkan</creator><creator>Şaşmaz, Hatice</creator><creator>Mutlu, Fezan</creator><creator>Güneş, Hakan</creator><creator>Mert, Uğur Kadir</creator><creator>Özdemir, Sedat</creator><creator>Kalaycı, Süleyman</creator><creator>Yılmaz, Mehmet Birhan</creator><general>Kare Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150801</creationdate><title>Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study</title><author>Çavuşoğlu, Yüksel ; Korkmaz, Şule ; Demirtaş, Selda ; Gencer, Erkan ; Şaşmaz, Hatice ; Mutlu, Fezan ; Güneş, Hakan ; Mert, Uğur Kadir ; Özdemir, Sedat ; Kalaycı, Süleyman ; Yılmaz, Mehmet Birhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-9ecbf667afae8faa95c86c16e6575189cd2e190b8a309a4bdde4e449a42142b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Cardiotonic Agents - administration & dosage</topic><topic>Dobutamine - administration & dosage</topic><topic>Female</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Hydrazones - administration & dosage</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Investigation</topic><topic>Prospective Studies</topic><topic>Pyridazines - administration & dosage</topic><topic>Serum Albumin</topic><topic>Serum Albumin, Human</topic><topic>Treatment Outcome</topic><topic>Turkey</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Çavuşoğlu, Yüksel</creatorcontrib><creatorcontrib>Korkmaz, Şule</creatorcontrib><creatorcontrib>Demirtaş, Selda</creatorcontrib><creatorcontrib>Gencer, Erkan</creatorcontrib><creatorcontrib>Şaşmaz, Hatice</creatorcontrib><creatorcontrib>Mutlu, Fezan</creatorcontrib><creatorcontrib>Güneş, Hakan</creatorcontrib><creatorcontrib>Mert, Uğur Kadir</creatorcontrib><creatorcontrib>Özdemir, Sedat</creatorcontrib><creatorcontrib>Kalaycı, Süleyman</creatorcontrib><creatorcontrib>Yılmaz, Mehmet Birhan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Anatolian journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Çavuşoğlu, Yüksel</au><au>Korkmaz, Şule</au><au>Demirtaş, Selda</au><au>Gencer, Erkan</au><au>Şaşmaz, Hatice</au><au>Mutlu, Fezan</au><au>Güneş, Hakan</au><au>Mert, Uğur Kadir</au><au>Özdemir, Sedat</au><au>Kalaycı, Süleyman</au><au>Yılmaz, Mehmet Birhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study</atitle><jtitle>Anatolian journal of cardiology</jtitle><addtitle>Anatol J Cardiol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>15</volume><issue>8</issue><spage>611</spage><epage>617</epage><pages>611-617</pages><issn>2149-2263</issn><eissn>2149-2271</eissn><abstract>Ischemia-modified albumin (IMA) is a sensitive biomarker of myocardial ischemia. However, data on IMA levels in acute heart failure (HF) are still lacking. In this study, we aimed to evaluate serum IMA levels in acute decompensated HF and the effects of dobutamine and levosimendan treatments on IMA levels.
This was a prospective, multicenter study that included 70 patients hospitalized with acute decompensated HF and left ventricular ejection fraction < 35%. Blood samples for IMA measurements were obtained on admission and 24-48 h after the initiation of HF therapy. Twenty-nine patients were treated with standard HF therapy, 18 received levosimendan, and 23 received dobutamine in addition to standard of care. A single serum specimen was also collected from 32 healthy individuals each. IMA concentrations were measured by the albumin cobalt binding colorimetric assay, and the results were given in absorbance units (AU). Independent and paired sample t-tests, Mann-Whitney U test, and Wilcoxon signed-rank test were used for the analysis.
In patients with acute decompensated HF, the serum concentration of IMA was significantly higher than those of healthy subjects (0.894 ± 0.23 AU vs. 0.379 ± 0.08 AU, p < 0.001). Overall, the IMA levels significantly decreased after 24-48 h of HF therapy (0.894 ± 0.23 AU and 0.832 ± 0.18 AU, p = 0.013). Furthermore, the IMA levels were also found to significantly decrease with standard HF therapy (1.041 ± 0.28 vs. 0.884 ± 0.15 AU, p = 0.041), with levosimendan (0.771 ± 0.18 vs. 0.728 ± 0.18 AU, p = 0.046) and also with dobutamine (0.892 ± 0.18 vs. 0.820 ± 0.13 AU, p = 0.035).
Patients with acute decompensated HF had elevated IMA levels, and appropriate HF therapy significantly reduced the serum IMA levels. Dobutamine or levosimendan did not increase the IMA levels, suggesting a lower potential in inducing myocardial ischemia when used in recommended doses.</abstract><cop>Turkey</cop><pub>Kare Publishing</pub><pmid>26301344</pmid><doi>10.5152/akd.2015.6156</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2149-2263 |
| ispartof | Anatolian journal of cardiology, 2015-08, Vol.15 (8), p.611-617 |
| issn | 2149-2263 2149-2271 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5336859 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adolescent Adult Aged Biomarkers - blood Cardiotonic Agents - administration & dosage Dobutamine - administration & dosage Female Heart Failure - blood Heart Failure - drug therapy Heart Failure - physiopathology Humans Hydrazones - administration & dosage Infusions, Intravenous Male Middle Aged Original Investigation Prospective Studies Pyridazines - administration & dosage Serum Albumin Serum Albumin, Human Treatment Outcome Turkey Young Adult |
| title | Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T20%3A54%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ischemia-modified%20albumin%20levels%20in%20patients%20with%20acute%20decompensated%20heart%20failure%20treated%20with%20dobutamine%20or%20levosimendan:%20IMA-HF%20study&rft.jtitle=Anatolian%20journal%20of%20cardiology&rft.au=%C3%87avu%C5%9Fo%C4%9Flu,%20Y%C3%BCksel&rft.date=2015-08-01&rft.volume=15&rft.issue=8&rft.spage=611&rft.epage=617&rft.pages=611-617&rft.issn=2149-2263&rft.eissn=2149-2271&rft_id=info:doi/10.5152/akd.2015.6156&rft_dat=%3Cproquest_pubme%3E3802379091%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1710671062&rft_id=info:pmid/26301344&rfr_iscdi=true |